Conference item icon

Conference item : Abstract

Dupilumab reduces risk of severe exacerbations and improves FEV1 in patients on both high- and medium dose ICS with uncontrolled, moderate-to-severe asthma from the phase 3 LIBERTY ASTHMA QUEST Study

Publication status:
Published
Peer review status:
Reviewed (other)

Actions


Access Document


Publisher copy:
10.1111/all.13539

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Target Discovery Institute
Oxford college:
St Edmund Hall
Role:
Author
ORCID:
0000-0002-4288-5973
Expand authors...
Publisher:
Wiley Publisher's website
Journal:
ALLERGY Journal website
Volume:
73
Issue:
S105
Pages:
463-464
Host title:
Allergy
Publication date:
2018-08-14
DOI:
ISSN:
0105-4538 and 1398-9995
Source identifiers:
915440
Subtype:
Abstract
Pubs id:
pubs:915440
UUID:
uuid:595ce41f-d52f-4eb1-b2ef-ad8917902cea
Local pid:
pubs:915440
Deposit date:
2018-11-15

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP